Horie Kazunori, Takahara Mitsuyoshi, Nakama Tatsuya, Tobita Kazuki, Tanaka Akiko, Shintani Yoshiaki, Tsubakimoto Yoshinori, Yoshioka Naoki, Hayakawa Naoki, Sasaki Shinya, Iwata Yo, Ogata Kenji, Takagi Tomonari, Doijiri Tatsuki, Fujihara Masahiko
Department of Cardiovascular Medicine, Sendai Kousei Hospital, Sendai, Japan.
Department of Diabetes Care Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
J Endovasc Ther. 2024 Feb 18:15266028241231472. doi: 10.1177/15266028241231472.
Surgical thromboendarterectomy has been the gold standard treatment for common femoral artery (CFA) disease. However, endovascular therapy (EVT) is conducted in certain patients with CFA lesions because of multiple comorbidities. The interwoven nitinol stent (IWS) has been developed to prevent stent fracture. Thus, this study aimed to evaluate the feasibility of EVT using IWS for CFA lesions in clinical practice.
This retrospective multicenter registry analyzed patients who had symptomatic lower-extremity artery disease due to CFA lesions and underwent EVT using IWS between 2019 and 2021. The primary endpoint was restenosis 2 years after EVT.
This study enrolled a total of 177 patients with 196 CFA lesions. The 2-year estimate of freedom from restenosis was 88.0%. The 2-year freedom rates from the target-lesion revascularization, major amputation, and all-cause death were 92.9%, 99.0%, and 75.2%, respectively. The clinical features significantly associated with restenosis risk were the reference vessel diameter (RVD, per 1.0 mm, hazard ratio [HR], 0.24 [0.08-0.70]; p=0.009), external iliac artery (EIA) involvement (HR=4.03 [1.56-10.4]; p=0.004), superficial femoral artery (SFA) involvement (HR=3.05 [1.00-9.25]; p=0.049), body mass index (BMI; per 1.0, HR=0.85 [0.73-0.99]; p=0.032), occlusion of deep femoral arteries (DFAs) at baseline (HR=7.89 [2.04-30.5]; p=0.003), and chronic limb-threatening ischemia (CLTI, HR=2.63 [1.02-6.78]; p=0.045). Their significant association was also confirmed by the random survival forest analysis. During a median follow-up of 12.0 months, guiding sheaths were inserted via CFAs implanted IWSs in 73 cases (37.2%), and no patients had cannulation-related complications, such as failed hemostasis, fracture of IWS, and stent occlusion.
Endovascular therapy using IWS in CFA lesions showed acceptable 2-year patency rates at 88.0% and might preserve the arterial access via the ipsilateral CFAs. Small RVD, involving EIA and SFA lesions, emaciation, occluded DFA, and CLTI are associated with poor 2-year patency rates following EVT, thus, IWS implantation in CFA lesions may be an option for patients unsuitable for surgical revascularization.
This retrospective multicenter registry enrolled 177 patients with 199 CFA lesions treated with EVT using interwoven nitinol stents, because surgical thromboendarterectomy was difficult due to their multiple comorbidities. The 2-year estimate of freedom from restenosis was acceptable at 88.0%. The 2-year freedom rate from major amputation was also high at 99.0%. Moreover, during a median follow-up of 12.0 months, guiding sheaths were inserted via CFAs implanted IWSs in 73 cases, and no patients had cannulation-related complications such as failed hemostasis, fracture of IWS, and stent occlusion.
外科血栓内膜切除术一直是股总动脉(CFA)疾病的金标准治疗方法。然而,由于存在多种合并症,某些患有CFA病变的患者会接受血管内治疗(EVT)。编织镍钛诺支架(IWS)已被研发出来以预防支架断裂。因此,本研究旨在评估在临床实践中使用IWS进行EVT治疗CFA病变的可行性。
这项回顾性多中心注册研究分析了2019年至2021年间因CFA病变出现症状性下肢动脉疾病并接受使用IWS的EVT治疗的患者。主要终点是EVT术后2年的再狭窄情况。
本研究共纳入177例患者,有196处CFA病变。2年无再狭窄的估计率为88.0%。2年免于靶病变血运重建、大截肢和全因死亡的发生率分别为92.9%、99.0%和75.2%。与再狭窄风险显著相关的临床特征包括参考血管直径(RVD,每增加1.0 mm,风险比[HR]为0.24[0.08 - 0.70];p = 0.009)、髂外动脉(EIA)受累(HR = 4.03[1.56 - 10.4];p = 0.004)、股浅动脉(SFA)受累(HR = 3.05[1.00 - 9.25];p = 0.049)、体重指数(BMI;每增加1.0,HR = 0.85[0.73 - 0.99];p = 0.032)、基线时股深动脉(DFA)闭塞(HR = 7.89[2.04 - 30.5];p = 0.003)以及慢性肢体威胁性缺血(CLTI,HR = 2.63[1.02 - 6.78];p = 0.045)。随机生存森林分析也证实了它们之间的显著关联。在中位随访12.0个月期间,73例(37.2%)患者通过植入IWS的CFA插入了引导鞘,且没有患者出现与插管相关的并发症,如止血失败、IWS断裂和支架闭塞。
在CFA病变中使用IWS进行血管内治疗显示出可接受的2年通畅率,为88.0%,并且可能保留同侧CFA的动脉入路。较小的RVD、累及EIA和SFA病变、消瘦、DFA闭塞以及CLTI与EVT术后2年的低通畅率相关,因此,在CFA病变中植入IWS可能是不适合外科血运重建患者的一种选择。
这项回顾性多中心注册研究纳入了177例患者,有199处CFA病变接受了使用编织镍钛诺支架的EVT治疗,因为由于他们存在多种合并症使得外科血栓内膜切除术困难。2年无再狭窄的估计率为88.0%,是可接受的。2年免于大截肢的发生率也很高,为99.0%。此外,在中位随访12.0个月期间,73例患者通过植入IWS的CFA插入了引导鞘,且没有患者出现与插管相关的并发症,如止血失败、IWS断裂和支架闭塞。